Published in Cancer Res on May 15, 2006
Studies on anticancer activities of antimicrobial peptides. Biochim Biophys Acta (2007) 3.24
From antimicrobial to anticancer peptides. A review. Front Microbiol (2013) 1.56
Synthesis and characterization of stable fluorocarbon nanostructures as drug delivery vehicles for cytolytic peptides. Nano Lett (2008) 1.47
Membrane-active host defense peptides--challenges and perspectives for the development of novel anticancer drugs. Chem Phys Lipids (2011) 1.45
In search of a novel target - phosphatidylserine exposed by non-apoptotic tumor cells and metastases of malignancies with poor treatment efficacy. Biochim Biophys Acta (2011) 1.36
Induction of cancer cell death by self-assembling nanostructures incorporating a cytotoxic peptide. Cancer Res (2010) 1.32
Structure, membrane orientation, mechanism, and function of pexiganan--a highly potent antimicrobial peptide designed from magainin. Biochim Biophys Acta (2008) 1.31
Oncolytic activities of host defense peptides. Int J Mol Sci (2011) 1.00
Antimicrobial peptides of the Cecropin-family show potent antitumor activity against bladder cancer cells. BMC Urol (2008) 0.98
Coassembled cytotoxic and pegylated peptide amphiphiles form filamentous nanostructures with potent antitumor activity in models of breast cancer. ACS Nano (2012) 0.97
A novel transferrin receptor-targeted hybrid peptide disintegrates cancer cell membrane to induce rapid killing of cancer cells. BMC Cancer (2011) 0.97
Small lytic peptides escape the inhibitory effect of heparan sulfate on the surface of cancer cells. BMC Cancer (2011) 0.88
Relative spatial positions of tryptophan and cationic residues in helical membrane-active peptides determine their cytotoxicity. J Biol Chem (2011) 0.87
Bax-derived membrane-active peptides act as potent and direct inducers of apoptosis in cancer cells. J Cell Sci (2011) 0.87
Enhancement of cytotoxicity of antimicrobial peptide magainin II in tumor cells by bombesin-targeted delivery. Acta Pharmacol Sin (2010) 0.86
Identification of a novel lytic peptide for the treatment of solid tumours. Genes Cancer (2014) 0.85
Host defense peptides for treatment of colorectal carcinoma - a comparative in vitro and in vivo analysis. Oncotarget (2014) 0.81
Novel antimicrobial peptides with high anticancer activity and selectivity. PLoS One (2015) 0.79
Rapid cytotoxicity of antimicrobial peptide tempoprin-1CEa in breast cancer cells through membrane destruction and intracellular calcium mechanism. PLoS One (2013) 0.79
Online monitoring of metabolism and morphology of peptide-treated neuroblastoma cancer cells and keratinocytes. J Bioenerg Biomembr (2011) 0.78
Roles of d-Amino Acids on the Bioactivity of Host Defense Peptides. Int J Mol Sci (2016) 0.77
Targeted delivery of a proapoptotic peptide to tumors in vivo. J Drug Target (2010) 0.76
Protease-activated pore-forming peptides for the treatment and imaging of prostate cancer. Mol Cancer Ther (2014) 0.76
D-K6L 9 peptide combination with IL-12 inhibits the recurrence of tumors in mice. Arch Immunol Ther Exp (Warsz) (2014) 0.76
Systemic Delivery of Tumor-Targeted Bax-Derived Membrane-Active Peptides for the Treatment of Melanoma Tumors in a Humanized SCID Mouse Model. Mol Ther (2017) 0.75
Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors. Cancer Chemother Pharmacol (2014) 0.75
Intramembrane attenuation of the TLR4-TLR6 dimer impairs receptor assembly and reduces microglia mediated neurodegeneration. J Biol Chem (2017) 0.75
Antimicrobial peptides with selective antitumor mechanisms: prospect for anticancer applications. Oncotarget (2017) 0.75
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res (2006) 7.09
Monocytes give rise to mucosal, but not splenic, conventional dendritic cells. J Exp Med (2006) 4.91
A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol (2009) 2.43
Perivascular clusters of dendritic cells provide critical survival signals to B cells in bone marrow niches. Nat Immunol (2008) 2.33
Ultrashort antibacterial and antifungal lipopeptides. Proc Natl Acad Sci U S A (2006) 2.15
MRI detection of transcriptional regulation of gene expression in transgenic mice. Nat Med (2007) 2.09
Recruitment of beneficial M2 macrophages to injured spinal cord is orchestrated by remote brain choroid plexus. Immunity (2013) 2.08
Transendothelial migration of lymphocytes mediated by intraendothelial vesicle stores rather than by extracellular chemokine depots. Nat Immunol (2011) 1.93
Kinetics of hyperpolarized 13C1-pyruvate transport and metabolism in living human breast cancer cells. Proc Natl Acad Sci U S A (2009) 1.93
Uterine DCs are crucial for decidua formation during embryo implantation in mice. J Clin Invest (2008) 1.82
Neuroprotection and progenitor cell renewal in the injured adult murine retina requires healing monocyte-derived macrophages. J Exp Med (2011) 1.80
Endotoxin (lipopolysaccharide) neutralization by innate immunity host-defense peptides. Peptide properties and plausible modes of action. J Biol Chem (2005) 1.72
Phosphocholine as a biomarker of breast cancer: molecular and biochemical studies. Int J Cancer (2007) 1.72
Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. J Clin Invest (2004) 1.70
Redirected tumor-specific allogeneic T cells for universal treatment of cancer. Blood (2011) 1.69
Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging--initial results. Radiology (2007) 1.67
Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol (2010) 1.63
Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice. Gastroenterology (2008) 1.61
T-cell inactivation and immunosuppressive activity induced by HIV gp41 via novel interacting motif. FASEB J (2006) 1.57
Conjugation of a magainin analogue with lipophilic acids controls hydrophobicity, solution assembly, and cell selectivity. Biochemistry (2002) 1.49
Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation. Blood (2004) 1.43
Use of lipophilic near-infrared dye in whole-body optical imaging of hematopoietic cell homing. J Biomed Opt (2006) 1.43
Can we predict biological activity of antimicrobial peptides from their interactions with model phospholipid membranes? Peptides (2003) 1.42
Water diffusion in the different microenvironments of breast cancer. NMR Biomed (2004) 1.40
Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. Cancer Res (2002) 1.40
Multiple genes in human 20q13 chromosomal region are involved in an advanced prostate cancer xenograft. Cancer Res (2002) 1.40
New lytic peptides based on the D,L-amphipathic helix motif preferentially kill tumor cells compared to normal cells. Biochemistry (2003) 1.37
Exploring peptide membrane interaction using surface plasmon resonance: differentiation between pore formation versus membrane disruption by lytic peptides. Biochemistry (2003) 1.33
In vivo imaging of the systemic recruitment of fibroblasts to the angiogenic rim of ovarian carcinoma tumors. Cancer Res (2007) 1.30
The consequence of sequence alteration of an amphipathic alpha-helical antimicrobial peptide and its diastereomers. J Biol Chem (2002) 1.30
Lipopolysaccharide (Endotoxin)-host defense antibacterial peptides interactions: role in bacterial resistance and prevention of sepsis. Biochim Biophys Acta (2006) 1.29
Bestowing antifungal and antibacterial activities by lipophilic acid conjugation to D,L-amino acid-containing antimicrobial peptides: a plausible mode of action. Biochemistry (2003) 1.25
Energetics of ErbB1 transmembrane domain dimerization in lipid bilayers. Biophys J (2009) 1.24
A new group of antifungal and antibacterial lipopeptides derived from non-membrane active peptides conjugated to palmitic acid. J Biol Chem (2004) 1.23
Magnetic resonance imaging reveals functional diversity of the vasculature in benign and malignant breast lesions. Cancer (2005) 1.23
A molecular mechanism for lipopolysaccharide protection of Gram-negative bacteria from antimicrobial peptides. J Biol Chem (2005) 1.23
Antimicrobial lipopolypeptides composed of palmitoyl Di- and tricationic peptides: in vitro and in vivo activities, self-assembly to nanostructures, and a plausible mode of action. Biochemistry (2008) 1.19
Photodynamic therapy with Pd-Bacteriopheophorbide (TOOKAD): successful in vivo treatment of human prostatic small cell carcinoma xenografts. Int J Cancer (2003) 1.19
Effect of drastic sequence alteration and D-amino acid incorporation on the membrane binding behavior of lytic peptides. Biochemistry (2004) 1.18
Model-based and model-free parametric analysis of breast dynamic-contrast-enhanced MRI. NMR Biomed (2009) 1.18
Transmembrane domains interactions within the membrane milieu: principles, advances and challenges. Biochim Biophys Acta (2011) 1.16
Suppression of human prostate tumor growth in mice by a cytolytic D-, L-amino Acid Peptide: membrane lysis, increased necrosis, and inhibition of prostate-specific antigen secretion. Cancer Res (2004) 1.15
Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity. J Biol Chem (2004) 1.14
Demonstrating the C-terminal boundary of the HIV 1 fusion conformation in a dynamic ongoing fusion process and implication for fusion inhibition. FASEB J (2007) 1.14
Two motifs within a transmembrane domain, one for homodimerization and the other for heterodimerization. J Biol Chem (2004) 1.14
Specificity in transmembrane helix-helix interactions mediated by aromatic residues. J Biol Chem (2007) 1.13
Viral fusion proteins: multiple regions contribute to membrane fusion. Biochim Biophys Acta (2003) 1.12
The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors. J Mol Biol (2004) 1.10
A novel lytic peptide composed of DL-amino acids selectively kills cancer cells in culture and in mice. J Biol Chem (2003) 1.10
Structurally altered peptides reveal an important role for N-terminal heptad repeat binding and stability in the inhibitory action of HIV-1 peptide DP178. J Biol Chem (2006) 1.09
Principal component analysis of breast DCE-MRI adjusted with a model-based method. J Magn Reson Imaging (2009) 1.08
Lipid clustering by three homologous arginine-rich antimicrobial peptides is insensitive to amino acid arrangement and induced secondary structure. Biochim Biophys Acta (2010) 1.08
Thermodynamics of melittin binding to lipid bilayers. Aggregation and pore formation. Biochemistry (2009) 1.07
Monitoring breast cancer response to neoadjuvant systemic chemotherapy using parametric contrast-enhanced MRI: a pilot study. Acad Radiol (2007) 1.07
Growth inhibition of prostate cancer xenografts by halofuginone. Prostate (2002) 1.07
Hormonal regulation of VEGF in orthotopic MCF7 human breast cancer. Cancer Res (2002) 1.07
Clinical testing of high-spatial-resolution parametric contrast-enhanced MR imaging of the breast. AJR Am J Roentgenol (2002) 1.07
DDM1 binds Arabidopsis methyl-CpG binding domain proteins and affects their subnuclear localization. Plant Cell (2005) 1.06
A synergism between temporins toward Gram-negative bacteria overcomes resistance imposed by the lipopolysaccharide protective layer. J Biol Chem (2006) 1.06
Conjugation of fatty acids with different lengths modulates the antibacterial and antifungal activity of a cationic biologically inactive peptide. Biochem J (2005) 1.06
D-alanylation of lipoteichoic acids confers resistance to cationic peptides in group B streptococcus by increasing the cell wall density. PLoS Pathog (2012) 1.05
Controlled alteration of the shape and conformational stability of alpha-helical cell-lytic peptides: effect on mode of action and cell specificity. Biochem J (2005) 1.05
Short native antimicrobial peptides and engineered ultrashort lipopeptides: similarities and differences in cell specificities and modes of action. Cell Mol Life Sci (2011) 1.04
Real-time imaging of lymphogenic metastasis in orthotopic human breast cancer. Cancer Res (2006) 1.04
In vitro activity and potency of an intravenously injected antimicrobial peptide and its DL amino acid analog in mice infected with bacteria. Antimicrob Agents Chemother (2004) 1.04
Parametric analysis of breast MRI. J Comput Assist Tomogr (2002) 1.03
Photodynamic therapy of established prostatic adenocarcinoma with TOOKAD: a biphasic apparent diffusion coefficient change as potential early MRI response marker. Neoplasia (2004) 1.03
Development of adoptive cell therapy for cancer: a clinical perspective. Hum Gene Ther (2010) 1.03
MRI analysis of angiogenesis during mouse embryo implantation. Magn Reson Med (2006) 1.02
Characterization of the HIV N-terminal fusion peptide-containing region in context of key gp41 fusion conformations. J Biol Chem (2006) 1.02
Permanent occlusion of feeding arteries and draining veins in solid mouse tumors by vascular targeted photodynamic therapy (VTP) with Tookad. PLoS One (2010) 1.01
Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. Cancer Res (2003) 1.01
Inhibition of fungal and bacterial plant pathogens in vitro and in planta with ultrashort cationic lipopeptides. Appl Environ Microbiol (2007) 1.01
pH-dependent antifungal lipopeptides and their plausible mode of action. Biochemistry (2005) 1.01
Glycolysis and glucose transporter 1 as markers of response to hormonal therapy in breast cancer. Int J Cancer (2003) 1.00
Oncolytic activities of host defense peptides. Int J Mol Sci (2011) 1.00
Functional and structural characterization of HIV-1 gp41 ectodomain regions in phospholipid membranes suggests that the fusion-active conformation is extended. J Mol Biol (2006) 1.00
Suppression of human solid tumor growth in mice by intratumor and systemic inoculation of histidine-rich and pH-dependent host defense-like lytic peptides. Cancer Res (2009) 1.00
Preassembly of membrane-active peptides is an important factor in their selectivity toward target cells. Biochemistry (2002) 1.00
C-terminal octylation rescues an inactive T20 mutant: implications for the mechanism of HIV/SIMIAN immunodeficiency virus-induced membrane fusion. J Biol Chem (2003) 0.99
Multifaceted action of Fuzeon as virus-cell membrane fusion inhibitor. Biochim Biophys Acta (2011) 0.99
HIV-1 gp41 transmembrane domain interacts with the fusion peptide: implication in lipid mixing and inhibition of virus-cell fusion. Biochemistry (2012) 0.99
Lipopolysaccharide, a key molecule involved in the synergism between temporins in inhibiting bacterial growth and in endotoxin neutralization. J Biol Chem (2008) 0.99
Comparative analysis of membrane-associated fusion peptide secondary structure and lipid mixing function of HIV gp41 constructs that model the early pre-hairpin intermediate and final hairpin conformations. J Mol Biol (2010) 0.99
Transcriptional regulation of vascular endothelial growth factor C by oxidative and thermal stress is mediated by lens epithelium-derived growth factor/p75. Neoplasia (2009) 0.98
Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor. Gastroenterology (2009) 0.97
Irradiation enhances the metastatic potential of prostatic small cell carcinoma xenografts. Prostate (2008) 0.97
Effect of the hydrophobicity to net positive charge ratio on antibacterial and anti-endotoxin activities of structurally similar antimicrobial peptides. Biochemistry (2010) 0.97
Parameters involved in antimicrobial and endotoxin detoxification activities of antimicrobial peptides. Biochemistry (2008) 0.97
Manipulation of redox signaling in mammalian cells enabled by controlled photogeneration of reactive oxygen species. J Cell Sci (2005) 0.97
Mechanistic and functional studies of the interaction of a proline-rich antimicrobial peptide with mammalian cells. J Biol Chem (2005) 0.96
On the interaction between gp41 and membranes: the immunodominant loop stabilizes gp41 helical hairpin conformation. J Mol Biol (2003) 0.96
Utilizing ESEEM spectroscopy to locate the position of specific regions of membrane-active peptides within model membranes. Biophys J (2005) 0.96
HIV-1 fusion peptide targets the TCR and inhibits antigen-specific T cell activation. J Clin Invest (2005) 0.96
Membrane-anchored HIV-1 N-heptad repeat peptides are highly potent cell fusion inhibitors via an altered mode of action. PLoS Pathog (2009) 0.95